Back |
home / stock / trypf / trypf message board
Subject | By | Source | When |
---|---|---|---|
Just wanna say Hi!! | Frenchy2016 | investorshub | 06/29/2021 2:03:43 PM |
Our CEO, President, and CFO will be providing | vegasandre | investorshub | 06/08/2021 5:22:18 PM |
TRYP CEO Greg McKee joined Steve Darling from | vegasandre | investorshub | 06/07/2021 4:25:19 PM |
Our recent partnership with | vegasandre | investorshub | 06/07/2021 2:11:20 PM |
Tryp Therapeutics Featured in USA Today | vegasandre | investorshub | 06/01/2021 2:48:08 PM |
As we enter our next phase of growth, | vegasandre | investorshub | 06/01/2021 2:44:17 PM |
NEWS-Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: $TRYPF) Brings | vegasandre | investorshub | 05/21/2021 2:12:52 PM |
TYRPF- OTCQB | vegasandre | investorshub | 04/28/2021 5:09:07 PM |
$TRYP- We have submitted a provisional patent | vegasandre | investorshub | 04/28/2021 5:08:13 PM |
twitter: @TrypTherapeutic | vegasandre | investorshub | 04/28/2021 5:07:19 PM |
$TRYP ANNOUNCES KEY MILESTONES FOR 2021: | vegasandre | investorshub | 04/28/2021 3:20:45 PM |
Going to be a major Mushroom player... | vegasandre | investorshub | 03/11/2021 8:20:47 PM |
About TRYP Therapeutics: | Golden Cross | investorshub | 02/26/2021 12:28:00 PM |
News, Short Squeeze, Breakout and More Instantly...
Tryp Therapeutics Inc Com Company Name:
TRYPF Stock Symbol:
OTCMKTS Market:
Kelowna, British Columbia--(Newsfile Corp. - May 17, 2024) - Tryp Therapeutics, Inc. (CSE: TRYP) (" Tryp " or the " Company ") announces, that it has filed amended financial statements for the six months ended February 29, 2024 (the " Financial Statements "), along with the corresponding Manage...
KELOWNA, BC / ACCESSWIRE / May 1, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP, OTCQB: TRYPF ) and Exopharm Limited ACN 163 765 991 (" Exopharm ") are pleased to announce that completion of the previously announced plan of arrangement (the " Arrangement ") effective ...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that shareholders of Exopharm Limited ACN 163 765 991 approved...